2011 Awards

ACP McElwain Prize

Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor, lapatinib in breast cancer
Alexandra Leary, The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK

Astrazeneca Student Prize Award

The AstraZeneca Student Prize Award is awarded to one high-quality abstract submitted by a student. AstraZeneca is proud to support excellence in research by young scientists. The recipient receives a bursary covering registration, accommodation and travel to the NCRI Conference. The 2011 Prize was awarded to:

Synthetic lethal targeting of DNA double strand break repair deficient cells by human apurinic/apyrimidinic endonucleaase (APE1) inhibitors
Rebeka Sultana et al., University of Nottingham, UK

BACR AstraZeneca Young Scientist Frank Rose Award

Role of an oncogenic enzyme sphingosine kinase 1 in the development of proinflammatory tumour microenvironment and prostate cancer chemoresistance
Dimitry Psheztskiy, Imperial College London, UK

BACR Translational Research Award

Epigenetic epidemiology: Exploring the epigenome to find biomarkers of cancer risk and prognosis
James Flanagan, Breast Cancer Campaign Fellow, Imperial College London, UK

British Association of Cancer Research (BACR)/Gordon Hamilton-Fairley Young Investigator Award

The BACR/Gordon Hamilton-Fairley Young Investigator Award recognises and encourages the talents of more junior cancer researchers. The winner of the 2011 Award was:

Systematic CpG islands methylation profiling of key signalling pathways identifies prognostic biomarkers for epithelial ovarian cancer
Wei Dai et al., Imperial College London, UK

Cancer Research UK Prize Award

Lifetime Achievement in Cancer Research Prize

The Cancer Research UK Lifetime Achievement in Cancer Research Prize honours an individual who has demonstrated a lifetime commitment to the fight against cancer, making exceptional advances in the field, and who has had a significant and sustained role in furthering our understanding of cancer or a major impact on the lives of people with cancer.

2011 Winner
Chris Marshall, The Institute of Cancer Research, London

Future Leaders in Cancer Research Prize

The Future Leaders in Cancer Research Prize recognises individuals who have completed their PhD within the last ten years and have demonstrated the potential to achieve world-leading status by producing international quality research.

The successful recipients of this prize will have produced international quality research, and demonstrated ambition and aspirations consistent with the potential exhibited by current world leaders at that stage of their career.

2011 Winners
Thomas Brunner, Gray Institute for Radiation Oncology & Biology, Oxford
Sarah Martin, Queen Mary, University of London, London

Translational Cancer Research Prize

The Translational Cancer Research Prize recognises an outstanding translational research team that has made seminal cancer research discoveries which are at the cutting edge of scientific novelty, and which have had significant impact on the continuing efforts to prevent, diagnose and cure cancer.

The prize-winning team is expected to be multidisciplinary, and comprise both clinical and non-clinical members – the team may also include principal investigators and non-principal investigators. Team members do not necessarily have to come from the same country or belong to the same institution; a significant proportion of the work that is being honoured must have been carried out in the UK.

2011 Winners
The Manchester Biomarkers Team, Paterson Institute for Cancer Research, Christie Hospital and AstraZeneca, Manchester

Children’s Cancer and Leukaemia Group (CCLG) Mcelwain Award

The CCLG McElwain Award will be given to the best poster in children’s cancer research. The winner of the 2011 Award was:

MiR-335 functions as a tumour suppressor in neuroblastoma cells through direct targeting of rock1, mapk1 and lrg1
Jennifer Lynch et al., Royal College of Surgeons in Ireland, Dublin, Ireland & National Children’s Research Centre, Dublin, Ireland

National Cancer Research Institute (NCRI) Prize Awards

The NCRI Prize Awards give PhD students who submitted an abstract as first author a prize bursary of up to £250 towards the cost of attending the Conference. Applicants for this award were asked why they chose to attend the NCRI Cancer Conference and how they feel they will benefit by attending. The winners of the awards were selected on the basis of both the quality of their abstract and the strength of their supporting application.
Measurement of cell death in vivo using magnetic resonance with TE-averaged PRESS and DTI
Lawrence Kenning et al., University of Hull, East Yorkshire, UK

mTOR inhibition modulates the synergistic inhibition of the PI3K and MEK pathways in colorectal carcinoma cell lines
Emma Haagensen et al., Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle upon Tyne, UK

Does human papillomavirus have a role to play in oral cavity squamous cell carcinoma?
Andrew Schache et al., University of Liverpool, Liverpool, UK & University Hospital Aintree, Liverpool, UK

Regulation of growth factor receptor signalling and trafficking by Ack1
Sylwia Krawczyk et al., University of Birmingham, UK

The leukemic fusion gene NUP98-HOXD13 impairs class switch recombination and antibody production
Abdul Gafoor Puthiyaveetil et al., Virginia Tech, Blacksburg, Virginia, USA

Epigenetic dysregulation of novel genes in melanoma
Hexiao Wang et al., Wellcome Trust Centre for Molecular Medicine and Biomedical Research Institute, College of Medicine, Dentistry and Nursing, Ninewells Hospital, University of Dundee, Dundee, UK

Preventing ovarian cancer: Developing a model of patient decision making about risk-reducing surgery in the context of genetic risk
Jana Witt et al., Cardiff University, Cardiff, UK

Polymorphism predisposes to high 17ß-estradiol levels depending on women’s metabolic profile. The EBBA-I study
Anita Iversen et al., University of Tromsø, Tromsø, Norway

Richard Hambro Student Prize

The Richard Hambro Prizes are awarded by Cancer Research UK and are supported by a generous donation from the Joint British Cancer Charities. Richard Hambro became involved with the Joint British Cancer Charities in the early 1980s through his step mother, the then Duchess of Roxburghe, who was President of the JBCC. Hambros Bank sponsored a Business Man of the Year lunch which raised substantial funds for the JBCC over many years. Richard Hambro was also Treasurer and subsequently Chairman of Macmillan Cancer Relief and oversaw its exceptional growth into a national charity over some twenty years. The Prizes support a bursary of up to £250 to the PhD students who, in the opinion of the conference planning committee, submitted the best abstracts. Three additional prizes were also awarded to the best posters.

1st prize for best poster presentation & recipient of bursary for best abstract

Novel mouse models for specific targeting and visualisation of lymphatic vasculature in vivo
Lukas Stanczuk et al., CR-UK London Research Institute, London, UK

Runner up for poster presentation & recipient of bursary for best abstract

Notch signalling mediates myofibroblast differentiation of carcinoma-associated fibroblasts
Ahmet Acar et al., Paterson Institute for Cancer Research, Manchester, UK & Breakthrough Breast Cancer Research Unit, Manchester, UK

Runner up for poster presentation & recipient of bursary for best abstract

Small molecule inhibitors of metabolic flux as potential antitumour agents
Jonathan Williams et al., University of Oxford, UK & Weatherall Institute of Molecular Medicine, University of Oxford, UK

Recipients of bursary for best abstract

The different genetic alterations between Western and Chinese prostate cancers indicate the aetiology
Xueying Mao et al., Queen Mary University of London, UK

Defining a spatially restricted aPKC/ERK phosphoproteome
Nick Peel et al., CR-UK London Research Institute, London, UK

Analysing paired array-comparative genomic hybridisation and gene expression microarray data: A novel method to infer gene relationships
Xin Yi Goh et al., MRC Cancer Cell Unit, Cambridge, UK & University of Cambridge, UK

SNW1 as a novel regulator of BMP signalling during early embryonic development
Sabine Reichert et al., CR-UK London Research Institute, London, UK

Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells are associated with colorectal metastatic tumour progression
Helen Angell et al., University of Nottingham, UK

HDAC6 inhibition down regulates c-FLIP and induces caspase 8-dependent apoptosis in colorectal cancer cells
Emma Kerr et al., Centre for Cancer Research and Cell Biology, Belfast, UK

Wnt/ ß-catenin regulation of embryonic NANOG (NANOG1) defines colorectal cancer stem cells and modulated by c-Jun/TCF4 transcriptional activity
Elsayed Ibrahim et al., University of Nottingham, UK

Identification and characterisation of GSK3b-phosphorylation dependent interactions of tumour suppressor gene Fbxw7
Ranjithmeon Muraleedharan et al., University of Nottingham, UK

Mechanisms of monoubiquitination in the Fanconi anaemia tumour suppressor pathway
Jennifer Miles et al., CR-UK London Research Institute, London, UK

TLR2 and TLR4 expression in inflammatory gastric lesion before and after Helicobacter pylori eradication therapy
Aline Cristina Targa Cadamuro et al., UNESP – São Paulo State University, São José do Rio Preto, Brazil

K-ras 146, N-ras 12/13, and N-ras 61 mutations in Quasar1 stage II/III colorectal cancers occur in 6% of cases. A small but important group?
Katie Southward et al., Leeds Institute of Molecular Medicine, UK

Imaging the development of functional tumour vasculature in vivo in preclinical models
Gemma Marston et al., University of Leeds, UK